Featured Research

from universities, journals, and other organizations

Experimental drug shows promise in lung cancer

Date:
October 29, 2013
Source:
University of California, Los Angeles (UCLA), Health Sciences
Summary:
MK-3475, an anti-PD1 immunotherapy drug with promising results in advanced trials in melanoma, is also showing potential in lung cancer based on preliminary phase 1b data. By blocking the PD-1 protein, the drug alerts the immune system to attack the cancer. It is generally well tolerated and further trials in lung cancer are currently underway.

An experimental new cancer drug called MK-3475, which has shown dramatic promise for treating melanoma is also showing early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death of men and women worldwide.

The preliminary results of a phase 1B study were presented by Dr. Edward Garon, director of thoracic oncology at UCLA's Jonsson Comprehensive Cancer Center, on Tuesday October 29 at the 15th World Conference on Lung Cancer. The summit was held by the International Association for the Study of Lung Cancer, in Sydney, Australia.

The detailed interim data were on safety and activity from a cohort of 38 previously treated non-small cell lung cancer (NSCLC) patients who received MK-3475 every three weeks. The response rate of patients given MK-3475 in this cohort was 24 percent. The median overall survival rate was 51weeks. Among the patients who responded, the median response duration had not been reached at the time of this analysis, and is at least 62 weeks. Based on this data, a phase II/III trial comparing two different doses of MK-3475 to standard chemotherapy for lung cancer has begun accruing patients.

Some cancer cells can evade detection by the human immune system by expressing a protein called PD-L1 that interacts with the protein PD-1, blocking the immune system from seeing the cancer as an invader. MK-3475, an anti-PD-1 immunotherapy drug made by Merck, enables the immune system to see the cancer as a problem and allows activation of T cells (the foot soldiers of the immune system) to attack and kill the cancer cells. The most commonly reported drug-related side effects in the study were rash (21 percent), skin itching (18 percent), fatigue (16 percent), diarrhea (13 percent) and joint pain (11 percent). Most side effects, however, were of low grade.

"These are early results, but we are very encouraged by what we've seen so far with this drug," Garon said. "Lung cancer patients who have disease that has grown after two prior therapies do not have many options and we are cautiously optimistic that this might be a treatment that improves their chances in the future."

According to the American Cancer Society, approximately 1.4 million people die from NSCLC every year, and it is the most common type of lung cancer, representing approximately 85 percent of all lung cancer diagnoses.


Story Source:

The above story is based on materials provided by University of California, Los Angeles (UCLA), Health Sciences. Note: Materials may be edited for content and length.


Cite This Page:

University of California, Los Angeles (UCLA), Health Sciences. "Experimental drug shows promise in lung cancer." ScienceDaily. ScienceDaily, 29 October 2013. <www.sciencedaily.com/releases/2013/10/131029142850.htm>.
University of California, Los Angeles (UCLA), Health Sciences. (2013, October 29). Experimental drug shows promise in lung cancer. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/10/131029142850.htm
University of California, Los Angeles (UCLA), Health Sciences. "Experimental drug shows promise in lung cancer." ScienceDaily. www.sciencedaily.com/releases/2013/10/131029142850.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins